Neuro-Oncology Department

Featured News

Mark Gilbert, M.D., professor and deputy chairman of neuro-oncology, presents at ASCO.

At the 2013 American Society for Clinical Oncology (ASCO) annual meeting, the Department of Neuro-Oncology was honored to have several members of our department presenting their exceptional work. The meeting brings together oncology professionals from a broad range of specialties to explore the given theme of the meeting – “Building Bridges to Conquer Cancer.” At the meeting, very important scientific studies, and only those with merit, are presented and discussed. We would like to recognize and congratulate the following ASCO 2013 presenters:

Neuro-Oncology Department

gilbert

The Department of Neuro-Oncology provides state-of-the-art treatment for patients with cancers of the brain and nervous system. Physicians in the department also provide expert care for patients that endure neurologic complications from cancer or cancer therapies. The department cares for more than 500 new patients with brain tumors each year.

The neuro-oncology team of skilled and experienced physicians participates in a multidisciplinary approach to cancer care — neurologists treat central and peripheral nervous system conditions that may affect cancer patients; neuropsychologists diagnose and treat cognitive and behavioral effects of cancer, or help patients learn ways to minimize cancer's impact on their quality of life. In addition, physicians in the department work with neurosurgeons, radiation oncologists, neuropathologists and neuroradiologists to plan a course of treatment that is unique and comprehensive for each patient. The physicians treat patients that are battling central nervous system tumors, including gliomas (glioblastoma multiforme, astrocytoma, brainstem glioma, ependymoma, oligodendroglioma), meningioma, vestibular schwannoma, central nervous system lymphoma, metastatic disease to the brain and spine, or primary spinal cord tumors.

Physicians in the department of Neuro-Oncology also specialize in genetic disorders. Neurofibromatosis is a genetic disorder that causes tumors to grow in the nervous system. The Neurofibromatosis Working Group provides exceptional care and treatment for patients with the disorder. It also works to translate laboratory advances into improved treatments for these patients. The group is a collaborative effort that includes Neuro-Oncology, Neurosurgery and Investigational Cancer Therapeutics.

Innovative Discoveries

research

Central to the department's mission is the discovery of new therapies for malignant and benign tumors and genetic disorders through clinical and laboratory research. In the laboratory, we test new therapeutic agents and approaches to gene therapy to target and kill cancer cells, or to disrupt the signaling pathways that control tumor growth. The Department of Neuro-Oncology is developing drug combination strategies that can overcome the tumor cell's ability to develop resistance to a single drug. Another important goal of the program is to develop and fund translational research so that therapies developed in the laboratory can be quickly brought to the clinical setting.